Publications by authors named "E Zanon"
Adeno-associated virus-based gene therapy (valoctocogene roxaparvovec) is an attractive treatment for hemophilia A. Careful clinical management is required to minimize the risk of hepatotoxicity, including assessment of baseline liver condition to determine treatment eligibility and monitoring liver function after gene therapy. This article describes recommendations (developed by a group of hemophilia experts) on hepatic function monitoring before and after gene therapy.
View Article and Find Full Text PDFArticle Synopsis
- - Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C), specifically Fanhdi® and Alphanate®, are commonly used to treat von Willebrand disease (VWD) in Italy, and a study evaluated their real-world effectiveness and safety.
- - The retrospective study involved 57 patients with different types of VWD, treating various bleeding episodes, surgical procedures, and long-term prophylaxis over a period from 2007 to 2019.
- - Results showed that pd-VWF/FVIII-C had excellent or good efficacy in 85% of bleeding episodes, 98% of surgeries, and 100% of long-term prophylaxis cases, with no serious safety concerns reported. *
Background: Opinions in the literature on the impact of cancer on patients with haemophilia are contradictory. There is a lack of data on the clinical presentation and management of cancer in patients with haemophilia (PWH).
Methods: Papers were found following a comprehensive search in PubMed, Google Scholar, and Scopus using the terms "cancer" and "haemophilia" without time limits and using the English language as a filter.
This study aimed to assess the effectiveness and costs associated with pharmacokinetics-driven (PK) prophylaxis based on the myPKFiT device in patients affected by hemophilia A (HA) in Italy. An observational retrospective study was conducted in three Italian hemophilia centers. All patients with moderate or severe HA, aged ≥ 18 years, capable of having PK estimated using the myPKFiT device, and who had had a clinical visit between 1 November 2019 and 31 March 2022 were included.
View Article and Find Full Text PDF